Poseida Therapeutics Stock (NASDAQ: PSTX)

Poseida Therapeutics (NASDAQ:PSTX) Stock, Quote.Headers.trade-ideas

Poseida Therapeutics

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ATXI

BALY

BIAF

BILI

BNED

CERO

EGOX

ELTK

GRPH

IMRN

ITRN

JFBR

LXEH

LXRX

MEDS

MESO

MNKD

MRAI

MRNA

MSTR

NBTX

NWTN

PLSE

PSTX

RVSN

SELX

SMCI

STAA

TCBP

VNET

VTYX

Shares of  Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients.

Mesoblast shares jumped 13.4% to $2.4399 on Monday.

Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

APLT

ARQT

ARWR

BITF

CVNA

Nuveen California Dividend Advantage Municipal Fund 2

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

Biotech

Health Care

General

RHHBF

RHHBY

RHHVF

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor 

Poseida Therapeutics&#39; New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial

Poseida Therapeutics, Inc. - Common Stock

Poseida Therapeutics Inc

WIIM

Poseida Therapeutics shares are trading higher after the company received Regenerative Medicine Advanced Therapy designation from the FDA for P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy Designation From The FDA For P-BCMA-ALLO1 In Relapsed/Refractory Multiple Myeloma

Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform
Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data
Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche
SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that new clinical data from an ongoing Phase 1 study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting, which is being held in Rio de Janeiro from September 25-28, 2024. The Company is developing P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy enriched for stem cell memory T cells (TSCM), in partnership with Roche for the treatment of relapsed/refractory multiple myeloma.

Contracts

Poseida Therapeutics To Present New Clinical Data From Phase 1 Study Of Allogeneic CAR-T P-BCMA-ALLO1 In Patients With Relapsed/Refractory Multiple Myeloma At 21st International Myeloma Society Annual Meeting; Initiation Of P-BCMA-ALLO1 Phase 1b Clinical Trial In Patients With Multiple Myeloma, Generated $20M Payment From Roche

Reactivation of P-BCMA-101&nbsp;CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy
Demonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs&nbsp;
SAN DIEGO, Sept. 4, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from a case study of a patient with relapsed multiple myeloma treated in a clinical trial of P-BCMA-101, the Company's original investigational T stem cell memory (TSCM)-rich BCMA targeting autologous CAR-T cell therapy. The data were presented in an oral session at the Society of Hematologic Oncology (SOHO) Twelfth Annual Meeting in Houston.

Poseida Therapeutics Presented Case Study Demonstrating Reactivation Of CAR-T Therapy With A T-Cell Engager In A Patient With Relapsed Multiple Myeloma

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is unchanged from the same period last year. The company reported quarterly sales of $25.97 million which beat the analyst consensus estimate of $15.43 million by 68.33 percent. This is a 29.78 percent increase over sales of $20.01 million the same period last year.

Earnings

Earnings Beats

Poseida Therapeutics Q2 EPS $(0.32) Beats $(0.41) Estimate, Sales $25.97M Beat $15.43M Estimate

<h3>Gainers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) stock moved upwards by 4.72% to $2.88. The market value of their outstanding shares is at $279.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 15.3% to $0.23 during Tuesday's after-market session. The company's market cap stands at $14.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock decreased by 14.88% to $0.4. The company's market cap stands at $5.6 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares decreased by 14.12% to $0.46. The market value of their outstanding shares is at $3.6 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock decreased by 11.5% to $3.31. The company's market cap stands at $122.1 million. </li>
<li>Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) stock declined by 8.89% to $7.28. The company's market cap stands at $462.1 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares decreased by 8.29% to $1.55. The company's market cap stands at $45.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

BSGM

CAPR

CDMO

CLDI

GOSS

IMRX

THMO

UNCY

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.42) by 40.48 percent. The company reported quarterly sales of $28.14 million which beat the analyst consensus estimate of $11.67 million by 141.22 percent. This is a 172.09 percent increase over sales of $10.34 million the same period last year.

Poseida Therapeutics Q1 2024 Adj EPS $(0.25) Beats $(0.42) Estimate, Sales $28.14M Beat $11.67M Estimate

Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profile
Preclinical P-FVIII-101 data highlight sustained Hemophilia A correction following a single dose and support potential for repeat dosing and precise tuning of Factor VIII levels
Promising early data further validate Company's fully non-viral delivery platform and transposon technologies
SAN DIEGO, May 9, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today highlights new preclinical data supporting the potential of its fully non-viral lead genetic medicines programs and related platform technologies. The data was included in three oral and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.

Poseida Highlights Progress On Its Genetic Medicine Programs At The American Society For Gene And Cell Therapy 27th Annual Meeting

- Leverages Poseida&#39;s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR&reg;&nbsp;programs targeting solid tumors -

ALPMY

Reported Earlier, Astellas And Poseida Therapeutics Enter Into Research Collaboration And License Agreement To Develop Novel Allogeneic Cell Therapies In Oncology

Poseida Therapeutics shares are trading higher after the company announced that it entered into a research collaboration and license agreement with Astellas to develop novel convertibleCAR programs.

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR&#xAE; programs targeting solid tumors -

Astellas And Poseida Therapeutics Enter Into Research Collaboration And License Agreement To Develop Novel Allogeneic Cell Therapies In Oncology

<h3>Gainers</h3>
<ul>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares rose 23.48% to $1.63. The market value of their outstanding shares is at $11.0 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 23.0% to $0.14. The company's market cap stands at $1.6 million. </li>
<li>Cullinan Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) shares moved upwards by 20.89% to $20.01. The company's market cap stands at $861.6 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock moved upwards by 18.85% to $76.97. The market value of their outstanding shares is at $7.4 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares moved upwards by 15.07% to $0.85. The market value of their outstanding shares is at $5.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares fell 24.3% to $8.32 during Tuesday's pre-market session. The company's market cap stands at $194.4 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 22.5% to $0.47. The market value of their outstanding shares is at $16.5 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) stock decreased by 20.06% to $0.24. The market value of their outstanding shares is at $1.5 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares declined by 12.69% to $21.61. The company's market cap stands at $22.8 million. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares fell 12.66% to $2.12. The market value of their outstanding shares is at $204.7 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares decreased by 10.38% to $1.21. The company's market cap stands at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

AKAN

ALZN

BRTX

CGEM

DRMA

DYNT

ITCI

ONVO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock increased by 70.1% to $0.63 during Monday's after-market session. The company's market cap stands at $3.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock rose 14.28% to $1.14. The company's market cap stands at $24.6 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares rose 12.61% to $8.84. The market value of their outstanding shares is at $45.8 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares moved upwards by 8.76% to $0.16. The company's market cap stands at $25.9 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares increased by 8.37% to $0.53. The company's market cap stands at $63.7 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares rose 7.87% to $0.53. The market value of their outstanding shares is at $29.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares declined by 15.2% to $2.06 during Monday's after-market session. The market value of their outstanding shares is at $198.7 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares fell 6.94% to $2.28. The market value of their outstanding shares is at $19.9 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares fell 6.74% to $0.11. The company's market cap stands at $30.6 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 6.4% to $0.26. The company's market cap stands at $4.0 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares declined by 6.26% to $0.65. The market value of their outstanding shares is at $23.2 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock declined by 5.81% to $2.76. The market value of their outstanding shares is at $8.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BIVI

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

HLTH

JAGX

LGVN

PIII

YTEN

12 Health Care Stocks Moving In Monday's After-Market Session

<ul>
<li>Promising early data suggest patients with relapsed/refractory multiple&nbsp;myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1, which was well tolerated</li>
<li>Following efforts to optimize allogeneic CAR-T therapy, Poseida is presenting a new data analysis underscoring the need for higher lymphodepletion chemotherapy doses when treating solid tumors vs. multiple myeloma</li>
</ul>
SAN DIEGO, April 8, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1. Results showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.
P-BCMA-ALLO1 is a novel investigational B-cell maturation antigen (BCMA)-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor T-cell (CAR-T) therapy manufactured from healthy donor T-cells and available off-the-shelf. These new Phase 1 study subgroup data and a new data analysis of different lymphodepletion regimens in patients treated with P-BCMA-ALLO1 for multiple myeloma or P-MUC1C-ALLO1 for solid tumors are being presented today in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
"Multiple myeloma remains incurable, and patients often relapse, despite initial high response rates with BCMA-targeted immunotherapies, including autologous CAR-T therapies," said Bhagirathbhai Dholaria, M.D., Associate Professor of Medicine (Hematology/Oncology) at the Vanderbilt-Ingram Cancer Center in Nashville, Tenn. "New treatment options are urgently needed for these patients, which is why I'm encouraged by these impressive Phase 1 subgroup results, which may be the first report of an allogeneic CAR-T therapy showing clinical activity in heavily pretreated patients whose myeloma has progressed after multiple BCMA-targeted immunotherapies."
"These new data build on the P-BCMA-ALLO1 data presented at ASH 2023, which demonstrated a 100% overall response rate in patients who had not been previously treated with a BCMA-targeted therapy. The new findings also provide additional evidence that our investigational, off-the-shelf allogeneic CAR-T therapy could be an appropriate treatment for a broader range of patients with multiple myeloma, including those with relapsed/refractory disease whose cancer progressed following prior&nbsp;BCMA-targeted therapy, representing the highest unmet need in this setting," said Syed Rizvi, M.D., Chief Medical Officer at Poseida. "In addition, we continue to explore the optimal lymphodepletion regimen for CAR-T in solid tumors and are directly applying these learnings to our P-MUC1C-ALLO1 trial with the goal of delivering the same benefits in solid tumors as we have seen in myeloma. We look forward to sharing more fulsome datasets on both our BCMA and MUC1-C programs in the second half of 2024."&nbsp;

Poseida Therapeutics Presents New Phase 1 Data At AACR 2024 Supporting Potential Of P-BCMA-ALLO1 Allogeneic CAR-T Therapy To Benefit Broad Range Of Patients With Multiple Myeloma

The markets are on a solid upward trend this year, with the year-to-date gain approaching 16%. Improved investor sentiment has been fueling the gai...

These 2 'Strong Buy' Penny Stocks Could Rally to $10 (or More), Say Analysts

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Poseida Therapeutics (PSTX – Research Report) and SAGE Therapeuti...

Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX) and SAGE Therapeutics (SAGE)

Poseida Therapeutics files for mixed shelf offering of up to $300M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Poseida Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pstx-stock-quote/">PSTX</a>) just reported results for the second quarter of 2024.<ul><li>Poseida Therapeutics reported earnings per share of -32 cents. This was above the analyst estimate for EPS of -41 cents.</li><li>The company reported revenue of $25.97 million.</li><li>This was 68.33% better than the analyst estimate for revenue of $15.43 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pstx-stock-earnings-poseida-therapeutics-for-q2-of-2024/">PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024

William Blair analyst Sami Corwin has maintained their bullish stance on PSTX stock, giving a Buy rating on July 25. Sami Corwin's rating is based ...

Buy Rating Affirmed for Poseida Therapeutics Amid Strategic Partnerships and Promising Clinical Developments

Analyst Arthur He CFA from H.C. Wainwright maintained a Buy rating on Poseida Therapeutics (PSTX – Research Report) and keeping the price target at...

Buy Rating Affirmed for Poseida Therapeutics Amidst Promising Clinical and Financial Updates

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Poseida Therapeutics (PSTX – Research Report) today and set a price target of $10....

Piper Sandler Keeps Their Buy Rating on Poseida Therapeutics (PSTX)

William Blair analyst Sami Corwin has maintained their bullish stance on PSTX stock, giving a Buy rating on August 6. Sami Corwin has given his Buy...

Buy Rating for Poseida Therapeutics: Strategic Partnerships and Innovative Cell Therapy Platform

In a report released today, Sami Corwin from William Blair maintained a Buy rating on Poseida Therapeutics (PSTX – Research Report). The company's ...

Poseida Therapeutics (PSTX) Gets a Buy from William Blair

Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

RZLT

SAGE

Press Releases

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024

Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Poseida Therapeutics

Poseida Therapeutics (PSTX) Forecast

Poseida Therapeutics (NASDAQ:PSTX) Stock, Quote.Headers.trade-ideas